A Combination of Glutaminase Inhibitor 968 and PD-L1 Blockade Boosts the Immune Response against Ovarian Cancer
Open Access
- 23 November 2021
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (12) , 1749
Abstract
Programmed cell death 1 ligand (PD-L1) blockade has been used therapeutically in the treatment of ovarian cancer, and potential combination treatment approaches are under investigation to improve the treatment response rate. The increased dependence on glutamine is widely observed in various type of tumors, including ovarian cancer. Kidney-type glutaminase (GLS), as one of the isotypes of glutaminase, is found to promote tumorigenesis. Here, we have demonstrated that the combined treatment with GLS inhibitor 968 and PD-L1 blockade enhances the immune response against ovarian cancer. Survival analysis using the Kaplan–Meier plotter dataset from ovarian cancer patients revealed that the expression level of GLS predicts poor survival and correlates with the immunosuppressive microenvironment of ovarian cancer. 968 inhibits the proliferation of ovarian cancer cells and enhances granzyme B secretion by CD8+ T cells as detected by XTT assay and flow cytometry, respectively. Furthermore, 968 enhances the apoptosis-inducing ability of CD8+ T cells toward cancer cells and improves the treatment effect of anti-PD-L1 in treating ovarian cancer as assessed by Annexin V apoptosis assay. In vivo studies demonstrated the prolonged overall survival upon combined treatment of 968 with anti-PD-L1 accompanied by increased granzyme B secretion by CD4+ and CD8+ T cells isolated from ovarian tumor xenografts. Additionally, 968 increases the infiltration of CD3+ T cells into tumors, possibly through enhancing the secretion of CXCL10 and CXCL11 by tumor cells. In conclusion, our findings provide a novel insight into ovarian cancer cells influence the immune system in the tumor microenvironment and highlight the potential clinical implication of combination of immune checkpoints with GLS inhibitor 968 in treating ovarian cancer.Keywords
Funding Information
- The Research Fund from Department of Obstetrics and Gynaecology, the University of Hong Kong. (Nil)
This publication has 58 references indexed in Scilit:
- Improving the Therapeutic Potential of Human Granzyme B for Targeted Cancer TherapyAntibodies, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune EscapeScience Translational Medicine, 2012
- Inhibition of Granzyme B by PI‐9 protects prostate cancer cells from apoptosisThe Prostate, 2011
- Granzyme B-induced apoptosis in cancer cells and its regulation (Review)International Journal of Oncology, 2010
- Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic TransformationCancer Cell, 2010
- Immune Response in Ovarian Cancer: How Is the Immune SystemInvolved in Prognosis and Therapy: Potential for Treatment UtilizationJournal of Immunology Research, 2010
- Q's next: the diverse functions of glutamine in metabolism, cell biology and cancerOncogene, 2009
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences, 2007
- Phosphate‐activated glutaminase expression during tumor developmentFEBS Letters, 1994